Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senzime ABFRA:6YC -4.68%59 3-1 Month Momentum % is -21.72% as of Aug. 29, 2026. GuruFocus rates FRA:6YC with a GF Score™ of 59/100 and a GF Value™ of €0.82. The stock has 3 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Senzime AB ranks worse than 80.82% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-29), Senzime AB's 3-1 Month Momentum % is -21.72%.
The industry rank for Senzime AB's 3-1 Month Momentum % or its related term are showing as below:
FRA:6YC's 3-1 Month Momentum % is ranked worse than 80.82% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: -6.21
vs FRA:6YC: -21.72
Senzime AB (FRA:6YC) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Senzime AB 3-1 Month Momentum % Related Terms
FRA:6YC vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Senzime AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Senzime AB's 3-1 Month Momentum % falls into.
Senzime AB (FRA:6YC) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senzime AB (FRA:6YC) has a 3-1 Month Momentum % of -21.72% as of Aug. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Senzime AB and its competitors. According to the industry distribution chart, Senzime AB ranks #687 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 80.8%.
Is Senzime AB's 3-1 Month Momentum % too high?
Senzime AB's current 3-1 Month Momentum % is -21.72%. Based on the distribution chart, Senzime AB ranks #687 out of 850 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Senzime AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #687 out of 850 companies for 3-1 Month Momentum %. This places Senzime AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Senzime AB and its competitors. Senzime AB's current 3-1 Month Momentum % is -21.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Senzime AB (FRA:6YC) has a current 3-1 Month Momentum % of -21.72%. The stock's GF Value™ is €0.82, compared to a current price of €0.30 — trading 64% below its estimated fair value. The current 3-1 Month Momentum % is -21.72%. Senzime AB's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Senzime AB (FRA:6YC), the current 3-1 Month Momentum % is -21.72% as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (FRA:6YC) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of €0.30 is trading 64% below its estimated GF Value™ of €0.82.
Key valuation signals for FRA:6YC:
3-1 Month Momentum %: -21.72%
GF Value™: €0.82 vs. price of €0.30 (64% below fair value)
No single metric tells the full story. See the FRA:6YC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
59GF Score
Get the complete analysis for FRA:6YC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YC has been successfully added to your 
